Építés alatt – nem éles oldal
Belépés
Leállítva1/2. fázis

Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy

A legfontosabb adatok

Ki végzi
Institute of Hematology & Blood Diseases Hospital, China
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Leállítva
Fázis
1/2. fázis
Résztvevők
6 fő vett részt
Kezdés
2023. máj. 5.
Befejezés
2025. márc. 30.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Selinexor
  • Venetoclax
  • Azacitidine
A regiszteradat frissítve
2025. május 30.
Miért állt le
The number of participants in the study did not meet expectations

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 14 feltétel megnézéseKevesebb

Ki vehet részt

  • Newly diagnosed AML patients diagnosed according to WHO standards who are not suitable for the standard induction treatment regimen of cytarabine combined with anthracycline drugs due to age or comorbidities
  • Age ≥ 75 years old, ECOG score 0-2 points; The patient's age range is 18-75 years old, with an ECOG score of 0-3
  • Liver function meets the following criteria: total bilirubin<3 × Upper limit of normal range (ULN) (<75 years old), total bilirubin<1.5 × ULN (≥ 75 years old), AST<3 × ULN and ALT<3 × ULN
  • Renal function meets the following criteria: creatinine clearance rate ≥ 30 mL/min (Cockroft-Gault formula)
  • Expected survival time greater than 6 months

Ki nem vehet részt

  • patient who has received BCL2 inhibitors, demethylation drugs, chemotherapy, CAR-T therapy, or other experimental therapies
  • I underwent major surgery within 4 weeks before the first study medication
  • History of myeloproliferative tumors (MPN)
  • Subjects with unstable or active cardiovascular diseases who meet any of the following criteria:
  • Symptomatic myocardial ischemia
  • Cytogenetic low risk, such as t (8; 21), inv (16), t (16; 16) or t (15; 17)
  • Acute promyelocytic leukemia
  • AML central nervous system (CNS) involvement
  • Pregnancy or lactation period

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study is a single arm open exploratory clinical trial to evaluate the efficacy and safety of selinexor combined with venetoclax and azacitidine. This study will be divided into two stages: dose increasing stage and dose expanding stage. In the dose-increasing stage, the study induction therapy was designed using a 3+3 design. The induction therapy and consolidation therapy of the subjects will be administered at RP2D doses.

A teljes eredeti leírásKevesebb

During this study period, there were a total of 4 cycles. The treatment cycle of the subjects will include 2 cycles of induction therapy and up to 2 cycles of consolidation therapy.

In addition, if the subject does not achieve remission (CR/Cr or PR) after 2 cycles of consolidation treatment (at the end of the 4th course), the study will be terminated by the subject, and the clinical doctor will choose the subsequent treatment for the subject based on clinical experience.

A vizsgálat csoportja

  • selinexor venetoclax AzacitidineA vizsgált kezelés

    In the dose-increasing stage, the subject induction therapy was designed using a 3+3 design. selinexor 60mg QW, 40mg BIW, or 60mg BIW, in combination with venetoclax 100mg d1 200mg d2 400mg d3-28, orally once a day, and azacitidine 75mg/m2, d1-7, subcutaneously. The medication regimen was repeated every 28 days. In this case, RP2D is determined based on MTD, safety, and all other data. During this study period, there were a total of 4 courses. The treatment cycle of the subjects will include 2 cycles of induction therapy and up to 2 cycles of consolidation therapy.

    Kezelés: Selinexor, Venetoclax és Azacitidine

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
An Exploratory Clinical Study of Selinexor Combined With Venetoclax and Azactidine in the Treatment of Acute Myeloid Leukemia Patients Who Are Not Eligible for Intense Chemotherapy Regimen at Initial Treatment
A regiszteradat frissítve
2025. május 30.